ClinicalTrials.gg
Not yet recruitingNCT07945652PAUSEUpdated Nov 18, 2026

Portable Absence Seizure Detection Using Smart Earbuds

An observational study in Epilepsy, Absence Epilepsy and Juvenile Absence Epilepsy, sponsored by Universitaire Ziekenhuizen KU Leuven. Not yet recruiting. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Primary conditionEpilepsy, AbsenceRegistry: EpilepsyReclassifiedWhy we changed it
Registry
Epilepsy — the first condition term the registry derived for this study.
ClinicalTrials.gg
Epilepsy, Absence
Why
  1. The study's listed conditions name Epilepsy, Absence, a narrower term within Epilepsy.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Universitaire Ziekenhuizen KU Leuven · Observational

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
25
Ages
6 Years and older
Sex
All
01

Study summary

Typical absence seizures are the hallmark of idiopathic generalized epilepsy syndromes (CAE, JAE, JME) but are frequently underreported in patient diaries. Clinical studies have shown that 74% to 94% of absence seizures go unreported by patients or caregivers. While 24-hour video-EEG (vEEG) is the gold standard for quantification, it is expensive, hospital-based, and lacks the temporal resolution required for long-term management.

Previous studies successfully validated a wearable EEG (wEEG) solution using a behind-the-ear (BTE) form factor (Byteflies Sensor Dot). In the pilot study, the authors demonstrated that a reduced electrode configuration combined with ML algorithms could detect absence seizures with 98% sensitivity in the hospital setting and enable effective home-based treatment monitoring.

To expand the applicability of this method, validation of additional form factors is required. This study aims to extend our validation framework to a novel wEEG device that utilizes an ear configuration (earEEG).

Read the detailed description
  1. Background, rationale and risk assessment

    1.1 Disease Background Typical absence seizures are the clinical hallmark of idiopathic generalized epilepsy syndromes, specifically Childhood Absence Epilepsy (CAE), Juvenile Absence Epilepsy (JAE), and Juvenile Myoclonic Epilepsy (JME)(1). These syndromes account for up to 20% of all people living with epilepsy, primarily affecting children, adolescents, and young adults(2). Clinically, absences are characterized by a transient loss of consciousness accompanied by generalized 3 Hz (2.5-5.5 Hz) spike-and-wave discharges (SWD) on the electroencephalogram (EEG). These seizures can have significant cognitive, affective, and behavioral comorbidities, particularly when not adequately controlled(1,3-5).

    1.2 Limitations of the Current Standard of Care Accurate quantification of the seizure burden is essential for optimizing the treatment with anti-seizure medications (ASM). The current standard of care relies on seizure diaries. However, previous studies indicate that the sensitivity of self-reporting for absence seizures ranges from 6% to 26% compared with video-EEG(6,7). i.e., seizure diaries have low reliability.

    Therefore, patients are intermittently followed with a 24-hour video electroencephalogram (vEEG), which has, among other limitations, high costs (approximately €1,200 per session in Belgium), long waiting times, and limited ecological validity, as they provide only a snapshot of the patient's condition that may not capture cyclical seizure variability(8).

    This study seeks to validate an objective, automated counting method using a wearable EEG (wEEG) device, first in a hospital setting and then at home.

    1.3 Rationale for Wearable EEG wEEG devices offer a promising alternative to full-scalp vEEG for long-term monitoring. By using a limited number of electrodes combined with Machine Learning (ML) algorithms, wEEG can enable intermittent or continuous, objective seizure counting outside the hospital.

    Researchers from ESAT-STADIUS \& UZ Leuven have previously validated this approach using a behind-the-ear (BTE) wEEG device (The Sensor Dot, Byteflies, Antwerpen, Belgium). In a pilot study, an ML algorithm developed by the group achieved 98% sensitivity for detecting absence seizures in a hospital setting compared to standard EEG(6). Furthermore, a subsequent home-based pilot demonstrated the feasibility of using this system for treatment optimization(9).

    1.4 Justification for the Current Investigation While the BTE form factor has been validated, it may not be the optimal solution for all patients due to cosmetic concerns, comfort, or lifestyle constraints. To facilitate widespread adoption and personalized care, it is necessary to validate alternative wEEG form factors, such as earEEG.

    The device under investigation in this study, the NeuroBuds™, uses a novel ear electrode configuration that lacks rigorous clinical validation against the gold standard for absence seizure detection.

    Therefore, the primary purpose of this study is to validate the signal quality and diagnostic accuracy of the ESAT-STADIUS ML algorithms on the signals recorded with the Neurobuds against simultaneous standard vEEG. This validation is a prerequisite for developing a device-agnostic ML algorithm capable of processing data from various manufacturers and electrode montages.

    1.5 Benefit/Risk Assessment The IMD is CE-marked, non-invasive, and poses minimal risk to participants, comparable to that of standard scalp EEG electrodes. The potential risks are limited to mild skin irritation or discomfort at the electrode sites. The potential benefit is the validation of a less invasive monitoring alternative. Successful validation may allow for future home-based seizure quantification.

  2. Investigation objectives \& design

2.1 Investigation objectives

Primary Objective The primary objective of this investigation is to validate the diagnostic accuracy of an investigational ear wEEG device, namely the NeuroBuds (Cebreo Medical), and an ML algorithm in detecting typical absence seizures. Specifically, the study aims to determine the sensitivity, precision, F1-score, and the FAR/24h of the ML seizure detection algorithm applied to signals recorded by the IMD, compared with simultaneous gold-standard video-EEG (vEEG) annotated by a neurologist.

Secondary Objectives

  1. Signal Quality: To assess the signal quality and artifact susceptibility of novel electrode form factors (earEEG) compared to standard wet scalp electrodes.
  2. Usability and Comfort: To evaluate patient and caregiver acceptance, comfort, and ease of use of the IMD in both hospital and home environments.
  3. Home Validation: To demonstrate the robustness of the data collection pipeline and algorithm performance in a real-world home environment, distinct from the controlled hospital setting.

Hypothesis In the hospital setting, the ML algorithm will achieve seizure-detection sensitivity of ≥90% (relative to simultaneous neurologist-annotated vEEG) after analyzing the data obtained with the IMD. These results should be comparable to those previously achieved with the BTE wEEG.

2.2 Primary endpoint

The primary endpoint is the diagnostic performance of the automated absence seizure detection algorithm using the investigational device data, measured by:

  • Sensitivity (Recall): The proportion of true absence seizures (defined as 3Hz Spike and Wave Discharges ≥ 3 seconds identified on the gold-standard vEEG) that are correctly detected by the wEEG algorithm.
  • Precision: the proportion of positive predictions that were actually correct when compared to the vEEG.
  • F1-score: a harmonic mean metric used to evaluate the overall performance of the ML model. It uses both precision and sensitivity.
  • False Alarm Rate (FAR): The number of false positive detections per 24 hours of recording.

2.3 Secondary endpoints

Signal Quality Metrics: Comparative hourly analysis of root mean square (RMS) and signal-to-noise ratio in the alpha band (SNR-Alpha) in the signals originated with the IMD channels and the spatially corresponding channels of the standard 10-20 EEG.

Usability Scores: Quantitative assessment of user experience (patients/caregivers) using standardized questionnaires (i.e., System Usability Scale, final questionnaire-comfort \& user experience, and User Perspective Questionnaire).

Data Yield: The percentage of interpretable (artifact-free) data obtained during unsupervised home recording sessions.

References

  1. Hirsch E, French J, Scheffer IE, et al. ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022;63(6):1475-1499. doi:10.1111/epi.17236
  2. Jallon P, Latour P. Epidemiology of Idiopathic Generalized Epilepsies. Epilepsia. 2005;46(s9):10-14. doi:10.1111/j.1528-1167.2005.00309.x
  3. Caplan R, Siddarth P, Stahl L, et al. Childhood absence epilepsy: Behavioral, cognitive, and linguistic comorbidities. Epilepsia. 2008;49(11):1838-1846. doi:10.1111/j.1528-1167.2008.01680.x
  4. Gruenbaum BF, Sandhu MRS, Bertasi RAO, et al. Absence seizures and their relationship to depression and anxiety: Evidence for bidirectionality. Epilepsia. 2021;62(5):1041-1056. doi:10.1111/epi.16862
  5. Callenbach PMC, Bouma PAD, Geerts AT, et al. Long-term outcome of childhood absence epilepsy: Dutch Study of Epilepsy in Childhood. Epilepsy Res. 2009;83(2-3):249-256. doi:10.1016/j.eplepsyres.2008.11.011
  6. Swinnen L, Chatzichristos C, Jansen K, et al. Accurate detection of typical absence seizures in adults and children using a two-channel electroencephalographic wearable behind the ears. Epilepsia. 2021;62(11):2741-2752. doi:10.1111/epi.17061
  7. Pizarro J, O'Sullivan S, Walker MC. How accurately do adult patients report their absence seizures? Epilepsia Open. Published online March 28, 2023:epi4.12689. doi:10.1002/epi4.12689
  8. Baud MO, Kleen JK, Mirro EA, et al. Multi-day rhythms modulate seizure risk in epilepsy. Nat Commun. 2018;9(1):88. doi:10.1038/s41467-017-02577-y
  9. Macea J, Chatzichristos C, Bhagubai M, De Vos M, Van Paesschen W. Tailoring antiseizure treatment with a wearable device: A proof-of-concept study in absence epilepsy. Epilepsia. 2025;66(7):2295-2306. doi:10.1111/epi.18384
02

Conditions studied

  • Epilepsy
  • Absence Epilepsy
  • Juvenile Absence Epilepsy
  • Juvenile Myoclonic Epilepsy
  • Absence Epilepsy, Childhood

Browse trials for

Keywords

  • Wearable device
  • Wearable EEG
03

In context

Epilepsy, Absence Reclassified

25 studies on the registry are indexed under Epilepsy, Absence; 2 are open to participants now.

Browse Epilepsy, Absence studies →

Lead sponsor

Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 965 studies on the registry; 269 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Compared within Epilepsy, Absence, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Epilepsy. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults and children with idiopathic generalized epilepsy syndromes and typical absence seizures.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary written of the participant or their legally authorized representative has been obtained prior to any screening procedures.
  2. At least 18 years of age at the time of signing the ICF or at least 6 years of age at the time their parents/legal representatives sign the caregiver's IFC and the minor participants sign the age-appropriate IFC.
  3. Confirmed diagnosis of the following idiopathic generalized epilepsy syndromes: CAE, JAE, or JME.
  4. Use of highly effective methods of ; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some Intra-Uterine Devices (IUDs), true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the investigation treatment(s)) or commitment to a vasectomised partner.
  5. Language: Subject and/or legal guardian must be able to understand the study instructions and the Informed Consent documents. These will be available in English and Dutch.

Exclusion criteria

Exclusion Criteria:

  1. Patient has a history of other generalized epilepsy syndromes, such as Lennox-Gastaut.
  2. Anatomical Constraints: Anatomical abnormalities of the outer ear or ear canal that prevent the proper fit of the earEEG device.
  3. Participation in another clinical trial with an drug or device that would interfere with the endpoints of this study.
  4. Female who is pregnant, breastfeeding, or intends to become pregnant or is of and not using an adequate, highly effective
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
25 participants (estimated)
Patient registry
No

Groups and cohorts

  • Absence patients

    Adults and children with idiopathic generalized epilepsy syndromes, i.e., Childhood Absence Epilepsy, Juvenile Absence Epilepsy, and Juvenile Myoclonic Epilepsy, with active disease and having typical absences. Prospective, single-center, open-label, comparative diagnostic accuracy study. Study participants will be contacted during the screening phase based on the scheduled admission for 24-hour vEEG in the epilepsy monitoring units of UZ Leuven. After screening and signing the IFC, they will be asked to come to the hospital for ear-mold imprinting. These prints will serve as the basis for customizing the headset. The study will employ a hybrid design, consisting of two phases: Phase A (In-Hospital Validation: participants will wear the IMD simultaneously with the standard 10-20 scalp EEG montage. This provides the ground truth labels for validation. Phase B (At home): participants will wear the device at least once a week for 3 weeks to assess real-world usability

06

What researchers measure

Primary outcomes

  1. Sensitivity (Recall)

    The proportion of true absence seizures (defined as 3Hz Spike and Wave Discharges ≥ 3 seconds identified on the gold-standard vEEG) that are correctly detected by the wEEG algorithm.

    Time frame: 1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)

  2. Precision

    The proportion of positive predictions that were actually correct when compared to the vEEG.

    Time frame: 1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)

  3. F1-score

    The harmonic mean metric used to evaluate the overall performance of the ML model. It uses both precision and sensitivity.

    Time frame: 1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)

  4. False Alarm Rate in 24 hours

    The number of false positive detections per 24 hours of recording.

    Time frame: 1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)

Secondary outcomes

  1. Signal quality

    Comparative hourly analysis of root mean square (RMS) and signal-to-noise ratio in the alpha band (SNR-Alpha) in the signals originated with the IMD channels and the spatially corresponding channels of the standard 10-20 EEG.

    Time frame: 1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)

  2. Usability Scores

    Quantitative assessment of user experience (patients/caregivers) using standardized questionnaires (i.e., System Usability Scale, final questionnaire-comfort \& user experience, and User Perspective Questionnaire).

    Time frame: 3 weeks, when the IMD will be used during 24 hours continuously at least once a week.

  3. Data Yield

    The percentage of interpretable (artifact-free) data obtained during unsupervised home recording sessions.

    Time frame: 3 weeks, when the IMD will be used during 24 hours continuously at least once a week.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Two years after the analysis, we will post the database, along with all measurements and code, on OpenNeuro.

Supporting information: Analytic code

Time frame: Two years after the analysis, we will post the database, along with all measurements and code, on OpenNeuro.

Access criteria: It will be open access

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Dec 2027, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Nov 18, 2026
StartEst.
Jan 11, 2027
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945652
Collaborators
Cebreo Medical
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Jan 11, 2027 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Jaiver Macea
Contact
jaiver.macea@uzleuven.be
+3216348273
Lauranne Scheldeman
principal investigator · UZ Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion